Pulmonary hemorrhage after percutaneous coronary intervention with abciximab therapy

被引：9

作者：

Choi, RK ^{[1
]}

Lee, NH ^{[1
]}

Lim, DS ^{[1
]}

Hong, SK ^{[1
]}

Hwang, HK ^{[1
]}

机构：

[1] Sejong Gen Hosp, Dept Internal Med, Puchon, South Korea

来源：

MAYO CLINIC PROCEEDINGS | 2002年 / 77卷 / 12期

关键词：

D O I：

10.4065/77.12.1340

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Abciximab has a key role in the treatment of patients with acute coronary syndromes undergoing percutaneous coronary intervention; however, an increased risk of bleeding complications is well recognized. We report a case of serious pulmonary hemorrhage after use of abciximab therapy. A definitive indication and treatment guideline should be available to minimize serious bleeding complications. Additionally, respiratory symptoms should be monitored closely for early detection of serious pulmonary hemorrhage in patients receiving abciximab therapy during percutaneous coronary intervention.

引用

页码：1340 / 1343

页数：4

共 17 条

[1] BLEEDING COMPLICATIONS WITH THE CHIMERIC ANTIBODY TO PLATELET GLYCOPROTEIN IIB/IIIA INTEGRIN IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION [J].

AGUIRRE, FV ;

TOPOL, EJ ;

FERGUSON, JJ ;

ANDERSON, K ;

BLANKENSHIP, JC ;

HEUSER, RR ;

SIGMON, K ;

TAYLOR, M ;

GOTTLIEB, R ;

HANOVICH, G ;

ROSENBERG, M ;

DONOHUE, TJ ;

WEISMAN, HF ;

CALIFF, RM .

CIRCULATION, 1995, 91 (12) :2882-2890

[2]

Ali A, 2000, CATHETER CARDIO INTE, V49, P181, DOI 10.1002/(SICI)1522-726X(200002)49:2<181::AID-CCD14>3.3.CO

[3]

2-A

[4] Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention [J].

Brown, DL ;

Fann, CSJ ;

Chang, CJ .

AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (05) :537-541

[5] USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY [J].

CALIFF, RM ;

SHADOFF, N ;

VALETT, N ;

BATES, E ;

GALEANA, A ;

KNOPF, W ;

SHAFTEL, J ;

BENDER, MJ ;

AVERSANO, T ;

RAQUENO, J ;

GURBEL, P ;

COWFER, J ;

COHEN, M ;

CROSS, P ;

BITTL, J ;

EDDINGS, K ;

TAYLOR, M ;

DEROSA, K ;

HATTEL, L ;

COOPER, L ;

ESHELMAN, B ;

FINTEL, D ;

NIEMYSKI, P ;

KLEIN, L ;

KENNEDY, H ;

THORNTON, T ;

KEREIAKES, D ;

MARTIN, L ;

ANDERSON, L ;

HIGBY, N ;

ELLIS, S ;

BREZINA, K ;

GEORGE, B ;

CHAPEKIS, A ;

SMITH, D ;

ANWAR, A ;

GERBER, TL ;

PRITCHARD, GL ;

MYLER, R ;

SHAW, R ;

MURPHY, M ;

WARD, K ;

MADIGAN, NP ;

BLANKENSHIP, J ;

HALBERT, M ;

FLANAGAN, C ;

TANNENBAUM, M ;

POLICH, M ;

STEVENSON, C ;

TCHENG, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) :956-961

[6] Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction [J].

Chan, AW ;

Chew, DP ;

Bhatt, DL ;

Moliterno, DJ ;

Topol, EJ ;

Ellis, SG .

AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (02) :132-136

[7] Alveolar hemorrhage as a complication of treatment with abciximab [J].

Kalra, S ;

Bell, MR ;

Rihal, CS .

CHEST, 2001, 120 (01) :126-131

[8]

Khanlou H, 1998, CATHETER CARDIO DIAG, V44, P313, DOI 10.1002/(SICI)1097-0304(199807)44:3<313::AID-CCD14>3.0.CO

[9]

2-L

[10] Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors [J].

Lincoff, AM ;

Califf, RM ;

Moliterno, DJ ;

Ellis, SG ;

Ducas, J ;

Kramer, JH ;

Kleiman, NS ;

Cohen, EA ;

Booth, JE ;

Sapp, SK ;

Cabot, CF ;

Topol, EJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (05) :319-327

← 1 2 →